

CITATION REPORT

List of articles citing

Anifrolumab: First Approval

DOI: 10.1007/s40265-021-01604-z
Drugs, 2021, 81, 1795-1802.

Source: <https://exaly.com/paper-pdf/82178634/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Epigenetic Alterations in Immune Cells of Systemic Lupus Erythematosus and Therapeutic Implications.. <i>Cells</i> , 2022 , 11,	7.9	1
20	Concepts in lupus pathophysiology: Lessons learned from disease across the spectrum.. <i>Clinical Immunology</i> , 2022 , 109021	9	0
19	Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.. <i>Human Vaccines and Immunotherapeutics</i> , 2022 , 2072143	4.4	1
18	Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment. <i>Expert Opinion on Biological Therapy</i> , 2022 , 22, 821-829	5.4	1
17	Dual Costimulatory and Coinhibitory Targeting with a Hybrid Fusion Protein as an Immunomodulatory Therapy in Lupus Nephritis Mice Models. 2022 , 23, 8411		
16	Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. 13,		1
15	Examining the autoimmune aspects of frontal fibrosing alopecia. 1-4		
14	Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. 13,		0
13	Identification and functional analysis of shared gene signatures between systemic lupus erythematosus and Sjögren's syndrome. 2022 , 2, 150-158		0
12	An update on the management of refractory cutaneous lupus erythematosus. 9,		1
11	Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021. 2022 , 10, 2325		1
10	ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus. 2022 , 8,		1
9	Chlorogenic Acid Relieves the Lupus Erythematosus-like Skin Lesions and Arthritis in MRL/lpr Mice. 2022 , 15, 1327		0
8	Autoimmune Pancreatitis: From Pathogenesis to Treatment. 2022 , 23, 12667		0
7	Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. 2022 ,		0
6	A Case of Rowell Syndrome with Excellent Improvement Following Anifrolumab. 2022 ,		0
5	Safety and Efficacy of Anifrolumab for Systemic Lupus Erythematosus: Network Meta-analysis. Publish Ahead of Print,		0

- 4 Developing engineering technologies for the treatment of systemic lupus erythematosus. **2023**, 4, 1-10
- 3 Immunomodulation – general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. 14,
- 2 Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies.
- 1 Combination strategies for lupus nephritis: facts and controversies. 1-10